280 related articles for article (PubMed ID: 22338015)
1. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP).
Kilday JP; Mitra B; Domerg C; Ward J; Andreiuolo F; Osteso-Ibanez T; Mauguen A; Varlet P; Le Deley MC; Lowe J; Ellison DW; Gilbertson RJ; Coyle B; Grill J; Grundy RG
Clin Cancer Res; 2012 Apr; 18(7):2001-11. PubMed ID: 22338015
[TBL] [Abstract][Full Text] [Related]
2. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
[TBL] [Abstract][Full Text] [Related]
3. Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification.
Andreiuolo F; Le Teuff G; Bayar MA; Kilday JP; Pietsch T; von Bueren AO; Witt H; Korshunov A; Modena P; Pfister SM; Pagès M; Castel D; Giangaspero F; Chimelli L; Varlet P; Rutkowski S; Frappaz D; Massimino M; Grundy R; Grill J;
PLoS One; 2017; 12(6):e0178351. PubMed ID: 28617804
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of chromosome 1q gain in intracranial ependymomas.
Rajeshwari M; Sharma MC; Kakkar A; Nambirajan A; Suri V; Sarkar C; Singh M; Saran RK; Gupta RK
J Neurooncol; 2016 Apr; 127(2):271-8. PubMed ID: 26725097
[TBL] [Abstract][Full Text] [Related]
5. Real-time quantitative PCR analysis of pediatric ependymomas identifies novel candidate genes including TPR at 1q25 and CHIBBY at 22q12-q13.
Karakoula K; Suarez-Merino B; Ward S; Phipps KP; Harkness W; Hayward R; Thompson D; Jacques TS; Harding B; Beck J; Thomas DG; Warr TJ
Genes Chromosomes Cancer; 2008 Nov; 47(11):1005-22. PubMed ID: 18663750
[TBL] [Abstract][Full Text] [Related]
6. Molecular staging of intracranial ependymoma in children and adults.
Korshunov A; Witt H; Hielscher T; Benner A; Remke M; Ryzhova M; Milde T; Bender S; Wittmann A; Schöttler A; Kulozik AE; Witt O; von Deimling A; Lichter P; Pfister S
J Clin Oncol; 2010 Jul; 28(19):3182-90. PubMed ID: 20516456
[TBL] [Abstract][Full Text] [Related]
7. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
[TBL] [Abstract][Full Text] [Related]
9. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.
Godfraind C; Kaczmarska JM; Kocak M; Dalton J; Wright KD; Sanford RA; Boop FA; Gajjar A; Merchant TE; Ellison DW
Acta Neuropathol; 2012 Aug; 124(2):247-57. PubMed ID: 22526017
[TBL] [Abstract][Full Text] [Related]
10. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
11. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
Chagtai T; Zill C; Dainese L; Wegert J; Savola S; Popov S; Mifsud W; Vujanić G; Sebire N; Le Bouc Y; Ambros PF; Kager L; O'Sullivan MJ; Blaise A; Bergeron C; Mengelbier LH; Gisselsson D; Kool M; Tytgat GA; van den Heuvel-Eibrink MM; Graf N; van Tinteren H; Coulomb A; Gessler M; Williams RD; Pritchard-Jones K
J Clin Oncol; 2016 Sep; 34(26):3195-203. PubMed ID: 27432915
[TBL] [Abstract][Full Text] [Related]
12. Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma.
Merchant TE; Bendel AE; Sabin ND; Burger PC; Shaw DW; Chang E; Wu S; Zhou T; Eisenstat DD; Foreman NK; Fuller CE; Anderson ET; Hukin J; Lau CC; Pollack IF; Laningham FH; Lustig RH; Armstrong FD; Handler MH; Williams-Hughes C; Kessel S; Kocak M; Ellison DW; Ramaswamy V
J Clin Oncol; 2019 Apr; 37(12):974-983. PubMed ID: 30811284
[TBL] [Abstract][Full Text] [Related]
13. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts.
Ellison DW; Kocak M; Figarella-Branger D; Felice G; Catherine G; Pietsch T; Frappaz D; Massimino M; Grill J; Boyett JM; Grundy RG
J Negat Results Biomed; 2011 May; 10():7. PubMed ID: 21627842
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups.
Ritzmann TA; Rogers HA; Paine SML; Storer LCD; Jacques TS; Chapman RJ; Ellison D; Donson AM; Foreman NK; Grundy RG
Pediatr Blood Cancer; 2020 Sep; 67(9):e28426. PubMed ID: 32614133
[TBL] [Abstract][Full Text] [Related]
15. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study.
Chapman RJ; Ghasemi DR; Andreiuolo F; Zschernack V; Espariat AT; Buttarelli FR; Giangaspero F; Grill J; Haberler C; Paine SML; Scott I; Jacques TS; Sill M; Pfister S; Kilday JP; Leblond P; Massimino M; Witt H; Modena P; Varlet P; Pietsch T; Grundy RG; Pajtler KW; Ritzmann TA
Neuro Oncol; 2023 Oct; 25(10):1871-1882. PubMed ID: 36916248
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma.
Pezzolo A; Capra V; Raso A; Morandi F; Parodi F; Gambini C; Nozza P; Giangaspero F; Cama A; Pistoia V; Garrè ML
Cancer Lett; 2008 Mar; 261(2):235-43. PubMed ID: 18179864
[TBL] [Abstract][Full Text] [Related]
17. Isochromosome 1q as an early genetic event in a child with intracranial ependymoma characterized by molecular cytogenetics.
Granzow M; Popp S; Weber S; Schoell B; Holtgreve-Grez H; Senf L; Hager D; Boschert J; Scheurlen W; Jauch A
Cancer Genet Cytogenet; 2001 Oct; 130(1):79-83. PubMed ID: 11672779
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas.
Cage TA; Clark AJ; Aranda D; Gupta N; Sun PP; Parsa AT; Auguste KI
J Neurosurg Pediatr; 2013 Jun; 11(6):673-81. PubMed ID: 23540528
[TBL] [Abstract][Full Text] [Related]
19. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group.
Robertson PL; Zeltzer PM; Boyett JM; Rorke LB; Allen JC; Geyer JR; Stanley P; Li H; Albright AL; McGuire-Cullen P; Finlay JL; Stevens KR; Milstein JM; Packer RJ; Wisoff J
J Neurosurg; 1998 Apr; 88(4):695-703. PubMed ID: 9525716
[TBL] [Abstract][Full Text] [Related]
20. Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial.
Upadhyaya SA; Robinson GW; Onar-Thomas A; Orr BA; Billups CA; Bowers DC; Bendel AE; Hassall T; Crawford JR; Partap S; Fisher PG; Tatevossian RG; Seah T; Qaddoumi IA; Vinitsky A; Armstrong GT; Sabin ND; Tinkle CL; Klimo P; Indelicato DJ; Boop FA; Merchant TE; Ellison DW; Gajjar A
Neuro Oncol; 2019 Oct; 21(10):1319-1330. PubMed ID: 30976811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
